U.S. Cardiology Market Size to Worth USD 36.66 Billion by 2034

The US cardiology market size accounted for USD 10.13 billion in 2024 and is predicted to touch around USD 36.66 billion by 2034, growing at a CAGR of 13.72% from 2025 to 2034. The U.S. cardiology market has been experiencing strong growth as a result of an increase in cardiovascular disease prevalence, the aging population, and improved interventions and diagnostic technology.

Highlights of the U.S. Cardiology Market

• By therapeutic application, the interventional cardiology device segment dominated the U.S. cardiology market and is anticipated to grow at the fastest rate.
• By therapeutic application, the peripheral vascular devices segment is expected to grow at a notable rate.

Industry Valuation and Growth Rate Projection

The U.S. cardiology market includes multiple types of diagnostic and therapy modalities and services like ECG machines, cardiac catheters, stents, pacemakers, echocardiography systems, and cardiac ablation modalities. These types of products and services are used across many different vectors, which include hospitals, specialty cardiac centers, ambulatory surgical centers, and rehabilitation clinics. While there may not be a distinct definition of cardiology, cardiology services are necessary to care for and treat various diseases and conditions like coronary artery disease, heart failure, arrhythmias, and valvular diseases.

The market features increasing growth due to the steadily increasing prevalence of heart-related diseases, especially in geriatric and obese patient populations. The rise in utilization of minimally invasive diagnostic and interventional technologies and increasing awareness of early symptom detection are causing the market to grow. The influence of the U.S. healthcare infrastructure, alongside increased funding into cardiovascular research, is sustaining growth. Although the hospital segment dominates the marketplace from an infrastructure perspective and the volume of patient cases, growth is rapidly occurring across the ambulatory surgical centers (ASCs) segment, which is benefiting from the availability of affordable and efficient outpatient cardiology services.

Based on CDC statistics, approximately 805,000 Americans have a heart attack every year, and the inherent need for cardiovascular services will never go away, given the growing pool of cardiovascular patients. There are also multiple factors driving the expanding, including developing remote cardiac monitoring technologies and more interventional cardiology treatments like angioplasty and stenting, which have led to lower mortality rates and improved patient outcomes.

U.S. Cardiology Market: Stats and Figures

• The Mayo Clinic is already applying AI-based ECG analysis, which can assess asymptomatic left ventricular dysfunction with >85% accuracy.
• As per the CDC, Cardiovascular disease is the leading cause of death in the US, accounting for nearly 1 in 5 deaths last year, with more than 702,220 deaths from heart disease.
• The Society of Thoracic Surgeons estimated that in 2023, there were more than 90,000 TAVR procedures completed in the U.S.
• In 2022, 702,880 people died from heart disease. That's the equivalent of 1 in every 5 deaths.

How Has AI Benefited the U.S. Cardiology Market?

Artificial intelligence (AI) is redefining the U.S. cardiology market through supporting earlier diagnosis, improved risk stratification, and better treatment planning. AI-developed and powered algorithms are being used for enhanced ECG (and echocardiogram) analysis to find atrial fibrillation, coronary artery calcification, and early symptoms of heart failure, greater than 85% ventricular dysfunction. AI is also advancing clinical decision-making via real-time analytics assessment in catheterization labs and reducing human error in the care and treatment of patients across the patient pathway. AI-based algorithms and natural language processing are now being integrated into EHR systems and are allowing for predictive modeling on the risk of heart attack and improved personalized management of patients across inpatient and outpatient practices.

Market Dynamics

What Are the Market Drivers in the U.S. Cardiology Market?

The U.S. cardiology market drivers include aging, sedentary lifestyles, and chronic conditions. At the same time, minimally invasive cardiac procedures are becoming the norm due to their lower risk, faster recovery, and cost-effectiveness, prompting increased investment in technology and infrastructure.

Rising prevalence of cardiovascular diseases

Cardiovascular disease is the leading cause of death in the US, accounting for nearly 1 in 5 deaths last year (American Heart Association, 2022). Conditions such as atherosclerosis, arrhythmias, heart failure, and valve disease are a lot more frequently occurring in older adults.

The high number of cardiovascular disease cases, such as coronary artery disease, hypertension, and atrial fibrillation, continues to increase the need for diagnostic services and care. The rising levels of sedentary behavior due to an increasing number of desk jobs, screen time, and lack of exercise, along with high levels of obesity and an increase in cases of Type 2 diabetes, have direct links to cardiovascular disease risk. Increasing job and life stresses lead to a spike in cortisol levels and chronic inflammation in the body, which also leads to higher cardiovascular disease risk. With over 122 million Americans living with some form of cardiovascular disease, the need for an expansion of more comprehensive cardiology care has never been higher, resulting hat increasing investments in infrastructure, technology, and workforce in the cardiology sector.

Surge in minimally invasive cardiac procedures

The U.S. market is experiencing a boom in minimally invasive cardiac procedures such as transcatheter aortic valve replacement, catheter-based ablation, and stenting. More patients are choosing minimally invasive procedures since they carry a lower risk of complications, allow shorter lengths of hospital stays, and allow for quicker recovery. The growing acceptance of outpatient procedures and same-day discharge protocols, especially among the elderly, is further facilitating this growth. As hospitals look to improve patient outcomes while lowering costs, investment and growth in minimally invasive cardiology show no signs of slowing down.

What Are the Restraints in the U.S. Cardiology Market?

The U.S. cardiology market faces major challenges due to a growing shortage of skilled specialists, particularly in rural areas, limiting access to timely and advanced care.

Shortage of properly trained cardiology health care providers

The U.S. cardiology market has a significant restriction with the increasing shortage of trained cardiologists and electrophysiologists. The Association of American Medical Colleges is currently projecting a shortfall of up to 7,080 cardiologists by 2034. Rural and underserved markets will struggle with these geographic and training issues, leaving access to timely and specialized cardiac care limited. A shortage not only affects existing specialists, but regional patients will wait longer, and reduce capacity for new cardiology technology and services.

Training professionals also takes years, and it could be extremely hard for hospitals and clinics to grow their cardiac programs to meet demand.

Long product development and approval time

Today's U.S. cardiology market is complicated by a rapidly changing and multifaceted regulatory and reimbursement environment. Innovative cardiac devices can take a long time and cost a lot of money to receive FDA approval, often requiring long clinical trials as well as significant affordability for both patients and payers, as well as serving human safety and efficacy assessments. In addition, while CMS reimbursement has changed, reimbursement has been inconsistent for cardiac ablation and cardiac remote monitoring, which is creating hesitation both for healthcare providers and device manufacturers. The inconsistencies make it especially difficult for emerging technologies to be adopted, particularly for small doctors' clinics that share environmental costs and ambulatory centers that are underfunding disruption costs for new technology. Plus, developing new codes and rules associated with value-based care and bundled payments are making billing increasingly complex and discouraging investment in innovative, yet expensive, cardiology devices, in particular.

What Are the Opportunities in the U.S. Cardiology Market?

U.S. cardiology market opportunities include AI-driven wearables, remote monitoring, and supportive policies that are expanding access to cardiac care in rural U.S. areas, driving innovation in portable, real-time cardiovascular solutions.

The emergence of AI-supported wearables and remote monitoring platforms creates an exciting opportunity not only to improve chronic disease management (cardiac detection) and access in the US, but we are also beginning to see policy makers support rural cardiac rehabilitation remotely, and better reimbursement by Medicare for a variety of digital health tools that help establish access, which further expands the opportunity. Taking cardiology outside of urban US development is also a key opportunity through working with mobile health units and telehealth partnerships in a rural health context, and for low-income individuals and families. Emerging trends in innovation are disrupting business models, especially start-ups and new device manufacturers, in providing portable, real-time CV care for underserved populations.

Industry Leader Announcements

• Senior author Natalia Trayanova, at Johns Hopkins University:

"Currently we have patients dying in the prime of their life because they aren't protected and others who are putting up with defibrillators for the rest of their lives with no benefit, We have the ability to predict with very high accuracy whether a patient is at very high risk for sudden cardiac death or not,"

• Anna Windle, PhD, Senior Vice President, NAO Clinical Development, Medical and Regulatory Affairs at Novo Nordisk Inc., said:

"Cardiovascular disease is the leading cause of death globally, disproportionately affecting people living with diabetes and obesity. It remains one of the most pressing diseases of our time and it carries a high clinical burden, we continue to build on our over 100-year legacy of cutting-edge science and innovation with data like we are sharing at ACC. It's foundational to who we are and how we continue to make a difference for people living with serious chronic disease."

Segmental Insights

Why Do Interventional Cardiology Devices Dominate, and Are Expected To Grow at the Fastest CAGR in the U.S. Cardiology Market?

Interventional cardiology devices lead the U.S. cardiology market by therapeutic application and are expected to grow at the fastest rate because their minimally invasive techniques for the treatment of coronary artery disease and structural heart abnormalities are increasingly preferred.

These commonly used devices, including stents, catheters, balloons, and transcatheter valve systems, offer rapid recovery and a safer alternative to more complex surgical procedures, including Transcatheter aortic valve replacement and angioplasty. The volume of these procedures and the patient population with multiple cardiac comorbidities, especially with an aging demographic in the United States, leads to a steady demand for these products. The advancement of technology with drug-eluting stents and bioresorbable scaffolds continues to lead to further improvements in long-term outcomes for the patient population of many comorbidities. With a decreased length of stay, the ability to provide enhanced precision on a case-by-case basis, combined with improved overall patient outcomes, tends to favor the use of these devices by hospitals and cardiac centers.

Why Is the Peripheral Vascular Devices Segment Expected To Grow at a Notable Rate in the Forecasted Period?

Peripheral vascular device is expected to grow at a notable rate in the U.S. cardiology market, driven by an increasing prevalence of peripheral artery disease (PAD), particularly amongst elderly and diabetic patient populations. Peripheral vascular devices are used to treat blockages or narrowing of arteries outside of the heart, primarily in the legs. In addition to a heightened understanding and awareness of the disease, there has also been an increase in PAD screening and the growing utilization of minimally invasive endovascular therapeutic devices for peripheral vascular disease. In addition, an overall trend toward more patient-centric approaches to early intervention and limb preservation has resulted in increased adult use of atherectomy systems, stent grafts, and angioplasty balloon devices. Furthermore, these outpatient procedures are supported by both the government and payers. Therefore, a unique combination of outpatient procedures and reimbursement has led to growth in this section of the cardiology device market.

Recent Developments in the U.S. Cardiology Market:

• In July 2025, Researchers in the U.S. developed an AI model that vastly improved the prediction applicability of sudden cardiac death. Using patient data, the model was able to identify subtle markers of risk that may not have been identified normally by traditional diagnostics. This novel approach aims to improve the early intervention approaches and better combat the number of lives lost to unknown cardiac events every year across the country.
• In May 2025, Novo Nordisk presented new cardiovascular data on semaglutide and other important medications as part of a "manufacturers review" on the updates to the ADA Guidelines on the 74th Annual Scientific Sessions of the American College of Cardiology. The results present evidence of LGBTQ benefits across many different chronic diseases including type 2 diabetes and obesity while highlighting the substantial role of semaglutide to reduce cardiovascular risk especially in groups of people at high-risk cardiovascular groups.
• In November 2024, Philips enrolled its first U.S. patient in a clinical trial to assess a new single-device integrated procedure for the treatment of peripheral artery disease. The new system improves upon previous technologies to combine previously separate treatment steps and optimizes the intervention, ultimately improving outcomes.
• In October 2024, U.S. News & World Report awarded the Kentucky Children’s Hospital for pediatric cardiology and made it one of the top institutions in the nation. The fact that Kentucky Children’s Hospital has advanced care, seasoned specialists, and a successful history of congenital heart disease made the decision easier for U.S. News & World Report.

Competitive Landscape

• Company Name: Abbott Laboratories
• Year of Incorporation: 1900
• Headquarters: Abbott Park, Illinois, U.S

Abbott Laboratories is a global healthcare firm that operates in more than 160 countries, selling cardiovascular devices, diagnostics, and nutritional products. Abbott's main products include MitraClip and XIENCE stents, with more research and development through Abbott Vascular to drive innovation in structural heart.

• Company Name: Boston Scientific Corporation
• Year of Incorporation: 1979
• Headquarters: Marlborough, Massachusetts, USA

Boston Scientific operates in more than 100 countries and develops medical devices to treat diseases and help perform procedures in Cardiology, Endoscopy, and Neuromodulation therapy. Boston Scientific has several marketable cardiovascular devices, including drug-eluting stents and Watchman. Dave is working with active Research and development for new drugs and evaluating new developments in minimally invasive cardiac therapies and therapies.

• Company Name: Medtronic
• Year of Incorporation: 1949
• Headquarters: Minneapolis, Minnesota, USA

Medtronic is a global healthcare company that operates in approximately 160 countries across the cardiovascular, neurology, and diabetes sectors. Medtronic manufactures industry-leading devices and therapies, including pacemakers and TAVR systems, and is currently investing in research and development into AI-enabled cardiac monitoring and robotics interventions.